Sbrt and Immunotherapy for Advanced Kidney Cancer
Part of Cancer, Immune system & allergy, Kidney & urinary clinical trials.
This trial studies whether combining a special type of radiation (SBRT) with an immunotherapy (PD-1 blocker) can shrink kidney cancer that has already spread. It is for people who have already had this combination treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced kidney cancer that has spread (stage IV).
- You have already received SBRT (a precise type of radiation) together with a PD-1 blocker (an immune therapy) for your kidney cancer.
- You have tumors that can be seen and measured on imaging scans.
- You do not have another cancer that is getting worse or needs active treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.